

2025 - 2026 Board of Directors

President

Frank S. Virant, MD, FAAAAI
University of Washington School of Medicine
Northwest Asthma & Allergy Center
Seattle, WA

President-Elect

Carla M. Davis, MD, FAAAAI
Howard University College of Medicine
Washington, DC

Secretary-Treasurer

Leonard B. Bacharier, MD, FAAAAI
Vanderbilt University Medical Center
Nashville, TN

Immediate Past-President

Paul V. Williams, MD, FAAAAI
University of Washington School of Medicine
Northwest Asthma & Allergy Center
Seattle, WA

At-Large Executive Committee Member

Anna H. Nowak-Wegrzyn, MD, PhD, FAAAAI
NYU Grossman School of Medicine
New York, NY

At-Large Board Members

Cem Akin, MD, PhD, FAAAAI
University of Michigan
Ann Arbor, MI

Priya J. Bansal, MD, FAAAAI
Asthma and Allergy Wellness Center
St. Charles, IL

Amy M. Dowden, MD, MME, FAAAAI
University of Iowa Hospitals and Clinics
Iowa City, IA

Angela Haczku, MD, PhD, FAAAAI
University of California-Davis School of Medicine
UC Davis Lung Center
Davis, CA

Anil Nanda, MD, FAAAAI
Asthma and Allergy Center
Lewisville, TX

Jordan S. Orange, MD, PhD, FAAAAI
Columbia University
New York, NY

Anju T. Peters, MD, MSCI, FAAAAI
Northwestern University Medical School
Chicago, IL

Allison Ramsey, MD, FAAAAI
Rochester Regional Health
University of Rochester
Rochester, NY

Rebecca Scherzer, MD, FAAAAI
Nationwide Children's Hospital
Columbus, OH

Marcus S. Shaker, MD, MS, FAAAAI
Dartmouth Hitchcock Medical Center
Lebanon, NH

Drew A. White, MD, FAAAAI
Scripps Clinic
San Diego, CA

Executive Vice President

Thomas A. Fleisher, MD, FAAAAI

Executive Director

Rebecca Brandt, CAE

Executive Director Emeritus

Kay Whalen, MBA, CAE

September 16, 2025

The Honorable Maxwell Frost
U.S. House of Representatives
1224 Longworth House Office
Building
Washington, DC 20515

The Honorable Doris Matsui
U.S. House of Representatives
2206 Rayburn House Office
Building
Washington, DC 20515

RE: Support for H.R. 5139, the *Epinephrine's Pharma Inflated Price Ends Now Act*

Dear Representatives Frost and Matsui:

I write on behalf of the American Academy of Allergy, Asthma & Immunology (AAAAI) to thank you for introducing H.R. 5139, the *Support for Epinephrine's Pharma Inflated Price Ends Now Act*. The AAAAI supports this legislation that would cap the price of epinephrine auto-injectors for individuals covered by private insurance.


Established in 1943, the AAAAI is a professional organization with more than 7,000 members in the United States, Canada and 72 other countries. This membership includes board certified allergist/immunologists, other medical specialists, allied health, and related healthcare professionals – all with a special interest in the research and treatment of patients with allergic and immunological diseases.

Anaphylaxis can result from insect stings, food items, and medications with 500-1,000 fatalities annually and many more hospitalizations and emergency department visits. The Centers for Disease Control and Prevention (CDC) reports that the prevalence of food allergies in children increased by 50 percent between 1997 and 2011. Between 1997 and 2008, the prevalence of peanut or tree nut allergy appears to have more than tripled in U.S. children. About 40 percent of children with food allergies have experienced a severe reaction, such as anaphylaxis. Each year, more than 200,000 Americans require emergency medical care for allergic reactions to food: equivalent to one trip to the emergency room every three minutes.

Importantly, H.R. 5139 would cap the cost of epinephrine delivery systems (including any auto-injector, nasal spray, or sublingual delivery system) in the private insurance market – making these lifesaving treatments more accessible and affordable for patients that suffer from severe allergic reactions. We would be happy to participate in discussion with you about potential opportunities to extend similar protections for patients who do not have insurance as well.

On behalf of the patients we serve, thank you for your leadership in lowering costs for patients with severe or life-threatening allergies. The AAAAI looks forward to working with you to advance this important legislation. Please contact Sheila Heitzig, JD, MNM, CAE, AAAAI Director of Practice and Policy, at (414) 272-6071 or sheitzig@aaaai.org if you have any questions.

Sincerely,

A handwritten signature in black ink that reads "Frank S. Virant". The signature is written in a cursive, flowing style.

Frank S. Virant, MD FAAAAI

President, American Academy of Allergy, Asthma & Immunology